Minoa (Levocarnitine)

Levocarnitine, the active ingredient in Minoa, is a nutritional supplement presented as an oral formulation for oral use. It supports energy metabolism by facilitating the transport of long‑chain fatty acids into mitochondria and is employed when carnitine levels are insufficient or metabolic support is required.

GNH USA supplies Minoa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levocarnitine is used to address conditions linked to impaired carnitine availability or mitochondrial fatty‑acid oxidation.

Primary Carnitine Deficiency: restores normal carnitine concentrations and improves muscle strength and energy. Secondary Carnitine Deficiency: replenishes depleted carnitine stores in patients undergoing dialysis or receiving certain medications. Inherited Fatty Acid Oxidation Disorders: supports mitochondrial β‑oxidation, helping to reduce metabolic crises and improve clinical stability.

Levocarnitine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional expulsion of stomach contents. - Abdominal discomfort: cramping or pain in the abdomen. - Diarrhea: loose stools occurring after dosing. - Headache: transient head pain. - Metallic taste: temporary alteration of taste perception.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or swelling. - Anaphylaxis: severe, life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Elevated liver enzymes: signs of hepatic stress. - Muscle weakness: unexpected loss of strength.

When prescribing Levocarnitine, consider the following safety measures.

Assess carnitine levels before initiating therapy: baseline testing guides dosing decisions. Monitor renal function in patients with kidney disease: impaired clearance may affect exposure. Avoid in patients with known hypersensitivity to levocarnitine: discontinue if allergic signs appear. Use caution in patients with seizure disorders: monitor for any change in seizure frequency. Store at ambient temperature (below 25°C): keep in the original pack, protect from moisture.

Levocarnitine may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Valproic acid co‑administration: may increase risk of hepatotoxicity. - Certain anticonvulsants (e.g., phenobarbital): can reduce levocarnitine efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: levocarnitine may alter INR values, requiring closer monitoring. - Carbapenem antibiotics: potential reduction in levocarnitine plasma levels. - Thyroid hormone therapy: possible influence on thyroid hormone activity.